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Abstract 
Letrozole (LTZ) is effective for the treatment of hormone-receptor-positive breast cancer 
in postmenopausal women. In this work, and for the first time, using Vibrating Orifice 
Aerosol Generator (VOAG) technology, monodisperse poly-ε-caprolactone (PCL) and 
poly (D, L-Lactide) (PDLLA) LTZ-loaded microparticles were prepared and found to elicit 
selective high cytotoxicity against cancerous breast cells with no apparent toxicity on 
healthy cells in vitro. Plackett-Burman experimental design was utilized to identify the 
most significant factors affecting particle size distribution to optimize the prepared 
particles. The generated microparticles were characterized in terms of microscopic 
morphology, size, drug entrapment efficiency and release profile over one-month period. 
Long-term cytotoxicity of the microparticles was also investigated using MCF-7 human 
breast cancer cell lines in comparison with primary mammary epithelial cells (MEC). The 
prepared polymeric particles were monodispersed, spherical and apparently smooth, 
regardless of the polymer used or the loaded LTZ concentration. Particle size varied from 
15.6 µm to 91.6 µm and from 22.7 µm to 99.6 µm with size distribution (expressed as span 
values) ranging from 0.22 to 1.24 and from 0.29 to 1.48 for PCL and PDLLA based 
microparticles, respectively. Upon optimizing the manufacture parameters, span was 
reduced to 0.162-0.195. Drug entrapment reached as high as 96.8%, and drug release from 
PDLLA and PCL followed a biphasic zero-order release using 5% or 30% w/w drug 
loading in the formulations. Long term in vitro cytotoxicity studies indicated that 
microparticles formulations significantly inhibited the growth of MCF-7 cell line over a 
prolonged period of time but did not have toxic effects on the normal breast epithelial cells.  
Keywords: vibrating orifice aerosol generator, controlled release, letrozole, 
monodisperse, microparticles, size distribution, cancer. 
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1. Introduction 
Letrozole (LTZ) is an FDA approved adjuvant therapy for the treatment of estrogen 
receptor (ER)-positive breast cancer in postmenopausal women [1]. Clinical trials have 
proven that LTZ can increase survival in breast cancer victims and reduce risk of recurrence 
and metastasis [2, 3]. Marketed oral formulations of LTZ may provide a non-linear release 
[4], resulting in plasma levels above the therapeutic window with concomitant severe 
adverse effects such as arthralgia, bone fractures, nausea, fatigue, and thromboembolic 
events [5]. Thus, it is highly desirable to design new delivery systems of LTZ with more 
predictable pharmacokinetic profiles in order to keep the plasma drug concentration below 
the toxic levels. 
Polymeric delivery systems may provide an approach to enhance solubility, prolong half-
life and reduce toxicity of many therapeutic molecules. Moreover, these systems can 
protect the drug from acid-induced degradation in the stomach, modulate drug release and 
improve pharmacokinetic properties of the drug [6]. In particular, poly (lactic-co-glycolic 
acid) (PLGA), poly (D,L-lactide) (PDLLA), and poly (-caprolactone) (PCL) have been 
widely used as drug carriers owing to their biocompatibility and biodegradability [7]. 
The utilization of different polymeric carriers to prepare LTZ formulations with improved 
characteristics has been reported. LTZ-PLGA particles have been prepared with drug 
entrapment efficiencies reaching up to 82% and a release profile that was greatly influenced 
by particle size distribution, with faster release and burst effects occurring when 
polydispersity of the particles is high [8, 9, 10, 11]. Whilst the definition of 
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‘monodispersity’ is not fully established, superior performance of particles is commonly 
attributed to their narrow size distribution; in this case and according to many reports, such 
particles are denoted as ‘monodisperse’. It has been realized that, designing monodisperse 
particulate systems could be advantageous compared to their higher size distribution 
(polydisperse) counterparts, in terms of providing uniform drug loading, controlled drug 
release and consistent pharmacokinetic properties. Accordingly, monodisperse particles 
(MDP) can potentially maximize benefits of therapy and reduce adverse drug effects [12, 
13, 14, 15, 16, 17, 18]. Furthermore, uniform distribution of the drug within monodisperse 
polymeric carriers may facilitate the prediction of drug release by calculating the overall 
surface area of the particulate system with respect to its volume, and the equivalent distance 
between the diffused drug particles and/or the rate of degradation of the carrier. Therefore, 
the progression towards in vivo studies would ascertain its effectiveness as that 
demonstrated by in vitro testing. The reliability on these calculations may decrease as the 
polydispersity of particles increases [12, 13].  
Many previous studies have reported on the benefits of carrier systems possessing narrow 
particle size distribution. For example, in pulmonary drug delivery systems, designing 
MDP can maximize their delivery to the target region of the lung and reduce the 
undesirable deposition in the upper airways [19, 20]. Likewise, systemic routes of 
administration such as in case of intravenous (IV) or intramuscular (IM) delivery of 
anticancer drugs in monodisperse systems can facilitate targeted embolization of tumor 
vessels [21].  
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Monodisperse drug delivery systems have been designed via chemical methods, e.g. by 
using a hypercross linking technique to prepare stable monodisperse particles [14]. 
Alternatively, physical approaches can also be employed. The Vibrating Orifice Aerosol 
Generator (VOAG) is an apparatus introduced by Berglund and Liu and is designed to 
produce a constant jet of monodisperse liquid droplets that dry off upon passing through a 
drying column, leaving the solutes that were dissolved in that liquid in the form of MDP 
[22]. To the best of our knowledge, this technology has not yet been explored to prepare 
solid MDP, owing to a number of limitations, such as low product yield, fluctuation of 
liquid pressure that builds upon passing through the tubes of the apparatus, clogging of the 
vibrating orifice, inefficient drying of the liquid feed, and difficulty of collecting the 
generated particles.  
We have recently reported on the preparation and characterization of letrozole-loaded 
PDLLA particles for drug delivery in breast cancer therapy using the conventional 
emulsion-solvent evaporation method [23]. In the present work, we have adapted the 
modified VOAG technology, aiming to generate solid MDP using PCL or PDLLA 
polymeric carriers loaded with the anticancer drug, LTZ. Production parameters such as 
drug loading, organic phase concentration, liquid flow rate, organic: aqueous phase ratio, 
stirring rate and others were screened to explore their effects on particle size and particle 
size distribution utilizing Plackett-Burman experimental design. The product yield, 
microscopic morphology and thermal properties of the solid MDP were studied. 
Furthermore, following dispersion in aqueous medium, particle size, size distribution and 
drug loading were investigated, and drug release was evaluated over a period of one month, 
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release data were fitted to a range of kinetic models to elucidate the underlying release 
mechanism. To evaluate the potential of the VOAG-generated LTZ-loaded MDP, long 
term cytotoxicity studies were conducted using the cancerous breast cell lines MCF-7 in 
comparison to the normal mammary epithelial cells (MEC). The findings of this study were 
appraised in light of the progress made with anticancer drug delivery using polymeric 
systems. To the best of our knowledge, this is the first study that utilized the VOAG system 
with the aim of designing monodisperse polymeric microparticles for providing prolonged 
drug release.   
2. Materials and methods   
2.1 Materials  
Letrozole (LTZ; purity 99%) was purchased from Jiangsu Sainty Handsome Co, Ltd, 
China. Poly (D, L-Lactic acid) (PDLLA; MW 15,000) and poly (-caprolactone) (PCL; 
MW 50,000) were purchased from Polysciences, Inc, PA, USA. Dichloromethane (HPLC 
gradient grade, 99.8%), polyvinyl alcohol (PVA; 88% hydrolyzed), polystyrene 
monodisperse microparticles (20 µm), and dialysis tubing cellulose membranes (MW cut-
off = 14,000 Da) were all purchased from Sigma-Aldrich Co. LLC, Germany. Acetonitrile 
gradient grade was obtained from Merck Co, Germany, and Transcutol® HP was obtained 
from Gattefossé, Lyon, France.  MCF-7 (ATCC® HTB-22™) cell line, primary mammary 
epithelial cells (MEC), normal Eagle's Minimum Essential Medium (EMEM), mammary 
epithelial cell basal medium, mammary epithelial cell growth kit, penicillin-streptomycin-
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amphotericin B solution, trypsin-EDTA Solution, trypsin neutralizing solution, Dulbecco's 
Phosphate Buffered Saline (D-PBS) were all purchased from ATCC®, VA, USA. All 
chemicals were used as received, without any further purification or chemical modification.  
2.2 Methods  
2.2.1 Preparation of polymeric microparticles using VOAG technology  
As illustrated in Figure 1, a modified VOAG system was used to enhance its efficiency in 
generating solid MDP. This was achieved by stabilizing the liquid pressure; thus, the 
Teflon O-ring (0.075 mm in thickness) that holds the orifice disc was replaced with a rubber 
O-ring (2 mm in thickness). To overcome clogging of the orifice, the orifice disc having a 
hole diameter of 20 μm was replaced with a specially manufactured orifice disc purchased 
from Lenox Laser, Inc. (MD, USA) with the following parameters: disc diameter: 9.5 mm 
± 0.26% mm, hole diameter: 300 μm ± 5% μm, thickness: 0.05 mm ± 5% mm, and 
centering: ± 0.25 mm. To overcome the inefficient drying that may lead to difficulty in 
collecting solid particles, the drying column was removed and the liquid orifice cup was 
inverted and mounted on a beaker containing a dispersion medium of 0.04-1% w/v PVA 
aqueous solution.  
A solution of 1 or 2 % w/v of PCL or PDLLA in DCM was prepared to which an amount 
equivalent to 5 or 30% w/w of LTZ was dissolved. The resultant organic solution was 
loaded into a syringe connected to the pump of the VOAG apparatus adjusted at a flow rate 
of 0.17-1.7 mL/min. Upon passing through the 300 µm orifice vibrating at a frequency of 
 8 
 
100-1000 kHz, a constant stream of monodisperse droplets was generated. The droplets 
were collected in a 0.04-1% w/v PVA aqueous medium which served as a stabilizer to 
prevent particle aggregation [24]. The ratio of the organic to aqueous media was in the 
range of 1:4 -1:8 v/v. The resultant dispersion was stirred at 250-500 rpm, at ambient 
temperature for 24 h to ensure complete solvent evaporation. Solidified microparticles 
were harvested through filtration, washed several times with distilled water to remove 
residual PVA, centrifuged at 8,500 rpm and 5°C for 10 min, and finally dried under vacuum 
at -19 kPa at 35°C for 48 h.  
 
Figure 1. A schematic presentation of the modified VOAG made to manufacture PCL and 
PDLLA based LTZ-loaded monodisperse microparticles. 
 
2.2.2 Experimental Design for Optimizing the Production Parameters   
Using Minitab® 17 Statistical Software (Coventry, UK), a 12-run, 2-level Plackett-Burman 
experimental design was created with each run containing a combination of two levels 
 9 
 
(high and low) of the following factors (independent variables): drug loading (X1), organic 
phase concentration (X2), organic: aqueous phase ratio (X3), PVA concentration (X4), 
frequency of the vibrating orifice (X5), liquid flow rate (X6), and stirring rate (X7) which 
are affecting particle size and specifically, particle size distribution (Y) (dependant 
variable). The highest and lowest levels for each independent variable were selected based 
on the reported results of previous studies in literature [25, 26, 27]. Table 1 lists the 
conditions of the 12 experiments with all of the different experimental. Each run was done 
in triplicate for each of the utilized polymeric carriers; PCL and PDLLA. Particles 
generated from each run were analyzed for their particle size distribution where the average 
span values were calculated and reported.  
Table 1: Plackett-Burman Design for Optimizing PCL- and PDLLA-based Formulations 
Formul
-ations 
X1 
(%w/w) 
X2 
(%w/v) 
X3  X4  
(%w/v) 
X5 
(kHz) 
X6 
(ml/sec) 
X7 
(rpm) 
F1 5 1 1: 8 0.1 1000 0.17 500 
F2 30 2 1: 4 0.1 100 0.17 250 
F3 30 1 1: 8 0.04 100 0.17 500 
F4 5 2 1: 8 0.04 1000 0.17 250 
F5 30 2 1: 4 0.1 1000 0.17 500 
F6 5 2 1: 8 0.1 100 1.7 500 
F7 30 2 1: 8 0.04 1000 1.7 250 
F8 5 2 1: 4 0.04 100 1.7 500 
F9 5 1 1: 4 0.04 100 0.17 250 
F10 5 1 1: 4 0.1 1000 1.7 250 
F11 30 1 1: 4 0.04 1000 1.7 500 
F12 30 1 1: 8 0.1 100 1.7 250 
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2.2.2  Scanning electron microscopy studies 
Scanning electron microscopy (SEM) studies were conducted by spreading 5-10 mg of the 
collected dried particles on a double-sided tape fixed on an aluminum holder, followed by 
spray-coating the sample with a gold film (thickness around 20 nm). Imaging was carried 
out at 15.0 kV using Nova NanoSEM® 450 scanning electron microscope (FEI, California, 
USA).   
2.2.3. Differential scanning calorimetry  
Thermal characteristics of the VOAG-generated solid particles were investigated using 
Differential Scanning Calorimetry (DSC) (DSC 8000, Perkin Elmer Co., USA) equipped 
with an intra-cooling system (Intra-cooler II, Perkin Elmer Co., USA). Samples (2-4 mg) 
of each formulation were placed into the DSC aluminum pans, each tightly sealed with an 
aluminum cover. Heating scans were conducted over a temperature range of 0 - 200°C or 
-70 - 200°C for PDLLA- and PCL-based formulations, respectively, at a heating rate of 
10°C/min. Samples were cooled down to either -70 oC or 0°C and then heated up to 200 
oC to record the DSC thermograms. Nitrogen gas flow was in operation throughout the 
experiments at 40 mL/min to eliminate humidity that might otherwise interfere with the 
thermal scanning. Pure samples of LTZ, PCL and PDLLA as well as LTZ-PCL, and LTZ-
PDLLA formulations were analyzed, with the aim of evaluating the crystalline properties 
of the samples. 
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2.2.4. Crystalline structure investigations using X-ray diffraction (XRD)  
Crystalline structure was further evaluated using X-ray diffraction (D8 Advance 
diffractometer, Bruker Co, Germany) via employing CuKα radiation source. Pure LTZ, 
PCL and PDLLA as well as LTZ-PCL, and LTZ-PDLLA formulations were analyzed using 
A1° divergence slit between the 2θ range 5-60 °C with a step size of 0.1°C and step time 
of 1 sec. DIFFRAC.EVA software was used to present the XRD patterns. 
2.2.5. Particle size analysis using laser diffraction  
Powder samples were dispersed in deionized water and analyzed at a temperature of 25°C 
by using the Malvern Mastersizer 2000 laser diffraction instrument (Malvern Instruments 
Ltd, UK). Particle size and size distribution were determined by measuring the median 
volume diameter (MVD) and span, respectively. The mean values of three samples 
obtained from three different batches were calculated for each formulation. Span was 
calculated based on the formula:  Span= (D90 - D10)/ D50, where D90, D10, and D50 
represent the median diameter by which 90%, 10%, and 50% of the size distribution has a 
smaller particle size than the given value of the equation [28, 29, 30].      
2.2.6. Determination of drug loading and entrapment efficiency 
Drug loading was determined by solubilizing specific quantities of the different 
formulations in 50 ml acetonitrile, followed by sonication for 10 min to ensure complete 
dissolution of the drug, and then LTZ concentration was measured via Ultra Performance 
Liquid Chromatography (UPLC) (Waters Co., USA). In all experiments, the mobile phase 
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used was acetonitrile and water (35:65 v/v), flowing at a rate of 0.3 ml/min, UV was set at 
240 nm, the column used was ACQUITY UPLC® BEH C18, 1.7 µm, and the column and 
sample temperature was set at 25 oC. Entrapment efficiency (EE) was determined by 
measuring the concentration of free drug (unentrapped) in the dispersion medium as 
reported previously [23]. In summary, LTZ-loaded microparticles dispersed in water was 
centrifuged using Sorvall® Stratos® Centrifuge (Fisher Scientific, USA) at 8500 rpm 
(14,400 g), -5 oC for 60 min using Centrisart® I tube (Sartorius GmbH, Germany), which 
consist of filter membrane (molecular weight cut-off 5,000 Da). The separated aqueous 
supernatant was then mixed with acetonitrile and assayed for unentrapped drug 
concentration by UPLC-UV set at 240 nm. The column used was ACQUITY UPLC® BEH 
C18, 1.7 µm, and the temperature was set at 25°C. The particles along with encapsulated 
LTZ remained in the outer chamber while the suspended and dissolved LTZ in the aqueous 
phase moved into the sample recovery chamber through the filter membrane. The amount 
of assayed unentrapped LTZ was subtracted from initial amount of LTZ to calculate drug 
entrapment efficiency of NPs. The percentage EE was calculated as follows: EE % = 
(Amount of drug recovered/Total amount of Drug used) *100.  The concentration of LTZ 
in the separated LTZ-loaded particles from supernatant was also quantified after extraction 
with dichloromethane to ensure the accuracy of determining the entrapment efficiency 
using the supernatant subtraction from the initial concentration of LTZ. The experiment 
was performed in triplicate for each batch and average drug EE was calculated. 
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2.2.7. In vitro drug release and kinetic modeling studies  
Drug release study was performed by using dialysis tubing cellulose membranes (MW cut-
off 14,000 Da). Known quantities of the dried LTZ-polymer loaded microparticles were 
suspended in 10 ml of the release medium which was composed of 0.1 M phosphate buffer 
saline (PBS, pH 7.4) with 20% v/v Transcutol® and filled in the dialysis tubes that were 
then sealed with their specified closures. The tubes were immersed in closed glass 
containers filled with 200 mL of the diffusion medium. These containers were placed in a 
shaking water bath (JULABO Labortechnik GmbH, Seelbach, Germany) adjusted at 
37±1°C and 100 rotations per min for one month. At specific intervals, 5 mL of the external 
medium was withdrawn, filtered, and injected into the UPLC to determine LTZ 
concentration. Similar volumes of fresh medium were used to replace the withdrawn 
samples and maintain the sink condition. Data were fitted into a range of kinetic models, 
which are zero-order, first order, Higuchi model, Hixson-Crowell model, and Korsemeyer-
Peppas semi-empirical model. For each model, both release rate constants (k) and 
correlation coefficients (R2) were determined by using the corresponding equations [31]. 
The model that provided R2 values that are closer to unity was considered the release order. 
2.2.8. Cytotoxicity studies and treatment of cells 
MEC and MCF-7 cells were cultured in mammary epithelial cell basal medium fortified 
with mammary epithelial cell growth kit and EMEM medium, respectively in 25 cm2 flasks 
at 37°C and 5% CO2. After one week, the cells were split and transferred into 75 cm2 flasks. 
The medium was changed every 2-3 days until the cells became 90-95% confluent and 
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were then harvested and used for cytotoxicity experiments. Cells were seeded in 96-well 
plates at a density of 10,000 cells/well and then incubated for 24 h at 37°C and 5% CO2 to 
enable the cells to recover and attach. After 24 h of incubation, cells were treated with 100 
nM, 1 µM, 10 µM, and 100 µM of LTZ from each formulation. Cells were treated with 
pure LTZ or polymeric LTZ-loaded MDP in EMEM medium containing acetonitrile and 
Transcutol® (1:5 v/v) to ensure complete solubility of LTZ in the medium after being 
released from the polymeric shell, while preserving the polymeric carriers intact. The 1:5 
v/v ratio was selected based on preliminary experiments (not shown) performed for optimal 
solubility. This was an important step to achieve an appropriate cellular uptake of LTZ. 
Consequently, to rule out the effects of the solvents on cell viability, three control groups 
were made. This was an important step to achieve an appropriate cellular uptake of LTZ. 
Simultaneously, three control groups were used to examine their individual as well as 
collective effect on cell viability. The first group consisted of acetonitrile and EMEM 
medium (1:5 v/v), the second consisted of Transcutol® and EMEM medium (5:1 v/v), and 
the third consisted of EMEM medium with a mixture of acetonitrile and Transcutol® (1:5 
v/v). Additionally, the effects of the polymeric carriers (PCL or PDLLA) were assessed by 
treating the MCF-7 cells with each blank polymer that contains no drug (the control group 
in Figures 8 and 9). Cytotoxicity was evaluated using nuclear staining after incubation of 
the treated cells for a period of 48 h.  
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2.2.9. Cytotoxicity measurement based on nuclear staining  
Following completion of treatment, MEC or MCF-7 cells were fixed with 4% v/v 
formaldehyde, followed by 0.1% v/v 4′,6-Diamidino-2-phenylindole dihydrochloride 
(DAPI) staining. Cell number was assessed through automated assessment of nuclear count 
using ArrayScan™ XTI Live High Content Platform (Thermo-Fisher Scientific, NY, USA) 
where 25 fields per well were selected for analysis. Number of viable cells was assessed 
by automated quantitation of DAPI positive nuclei using target activation module (HCS 
Studio® Cell Analysis Software), following exclusion of apoptotic nuclei distinguished by 
their collapsed size, higher chromatin intensities and nuclear fragmentation [32].  
2.2.10. Statistical analysis 
Results were reported as mean ± Standard Deviation (SD) for the different parameters 
assessed. Student’s t-tests and One-Way Analysis of Variance (ANOVA) were used to 
compare between the independent variables, for two groups and more than two sets of data, 
respectively. For this purpose, IBM Statistical Package for Social Sciences (IBM SPSS® 
Statistics - version 21) was used, and the difference was considered statistically significant 
when the calculated p-value was less than 0.05. Minitab® 17 Statistical Software (Coventry, 
UK) was used to run the Plackett-Burman experimental design. 
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3. Results and discussion 
3.1 Experimental Design for Optimizing the Production Parameters   
Multiple factors involved in the production process of MDP were reported to have an effect 
on particle size distribution including drug loading, organic phase concentration, organic: 
aqueous phase ratio, PVA concentration, frequency of the vibrating orifice, liquid flow 
rate, and stirring rate [33]. Therefore, it was essential to study the effects of these factors 
on particle size distribution in order to determine the optimal values of each one that would 
yield optimal MDP. Thus, a screening of those factors that were thought to have an impact 
on particle size distribution was undertaken based on Plackett-Burman design which is a 
powerful tool that allows the accurate identification of major factors influencing an 
outcome with the least number of experiments. This is because Plackett-Burman design is 
a fractional factorial design that combines the advantage of accuracy of full factorial 
designs and the few experimental runs of fractional factorial designs [25, 26, 27]. 
A 12-run, 2-level Plackett-Burman design was created with each run containing a different 
combination of high or low levels of each factor as listed previously in Table 1. The 
different factor combinations resulted in a wide variation in both particle size and particle 
size distribution. As listed in Table 2, the average particle size ranged from 15.6 ± 1.1 µm 
to 91.6 ± 2.0 µm for PCL-based formulations, whereas PDLLA-based formulations had a 
particle size range of 22.7 ± 0.70 µm to 99.6 ± 3.1 µm. A large variation in particle size 
distribution was also observed among the different formulations in which the span values 
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ranged from 0.22 ± 0.02 to 1.24 ± 0.27 and from 0.29 ± 0.04 to 1.48 ± 0.36 in PCL-based 
and PDLLA-based formulations, respectively (Table 2).  
Table 2: Summary of the particle size and particle size distribution analyses for 
formulations run in Plackett-Burman design  
Formulation 
PCL-based Microparticles PDLLA-based Microparticles 
Mean diameter 
(µm) 
Span Mean diameter 
(µm) 
Span 
F1 47.9 ± 1.9  0.52 ± 0.03 59.2 ± 1.1 0.60 ± 0.02 
F2 47.0 ± 2.4  0.56 ± 0.03 53.3 ± 3.2  0.59 ± 0.04 
F3 33.4 ± 2.7  0.37 ± 0.03 44.0 ± 3.4  0.44 ± 0.04 
F4 58.7 ± 1.5  0.60 ± 0.02 64.0 ± 2.3  0.59 ± 0.07 
F5 15.6 ± 1.1  0.22 ± 0.02 22.7 ± 0.70  0.29 ± 0.07 
F6 91.6 ± 2.0  1.24 ± 0.27 99.6 ± 3.1  1.48 ± 0.36 
F7 47.1 ± 2.4  0.58 ± 0.04 58.0 ± 5.6  0.61 ± 0.05 
F8 57.9 ± 1.8  0.60 ± 0.04 61.1 ± 4.8  0.61 ± 0.09 
F9 61.8 ± 3.2  0.61 ± 0.05 46.6 ± 2.3  0.57 ± 0.09 
F10 76.7 ± 2.4  0.88 ± 0.03 84.2 ± 2.9  0.93 ± 0.04 
F11 17.4 ± 1.2  0.26 ± 0.04 24.0 ± 2.6  0.29 ± 0.04 
F12 88.7 ± 1.3  1.15 ± 0.22 97.8 ± 3.0  1.46 ± 0.36 
 
Regression analysis allowed the accurate elucidation of the effects of each factor on particle 
size distribution; span (Y) through the following equation for PCL-based formulations:  
Yspan-PCL= 0.397 - 0.00876 X1 + 0.0033 X2 + 0.0561 X3 + 4.296 X4 - 0.000273 X5 + 
0.1983 X6 - 0.000773 X7. On the other hand, PDLLA-based formulations had a different 
equation, but with a similar pattern to these observed in PCL-based formulations. The 
equation illustrating the effects of each factor on particle size distribution; span (Y) for 
PDLLA-based formulations was:  Yspan-PDLLA= 0.169 - 0.00724 X1 + 0.0211 X2 + 0.0786 
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X3 + 6.26 X4 – 0.000338 X5 + 0.2505 X6 – 0.000702 X7. Both equations were highly 
accurate in predicting the span values for each formulation through setting the 
parameters/factors at their optimal levels to ensure achieving the lowest span values 
possible before running the experiment. As shown in Figure 2, a strong correlation was 
established between the predicted and observed span values using these equations with a 
multiple regression coefficient (R2) equivalent to 0.9668 and 0.9521 for PCL- and PDLLA-
based formulations, respectively.  
 
Figure 2: Correlation between observed and predicted span values by the model for (A): 
PCL- based microparticles and (B): PDLLA-based microparticles. 
 
 
ANOVA statistical analyses revealed that all production parameters/factors had a 
significant effect on particle size distribution (p< 0.05), except for organic phase 
concentration X2 (p = 0.955) in PCL-based formulations (Table 3). However, drug loading 
(X1), organic phase concentration (X2), and stirring rate (X7) were found to have no 
significant impact on particle size distribution when PDLLA was used (Table 3). Such 
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interesting observations were made previously when different polymeric carriers were used 
owing to the differences in their intrinsic characteristics [25, 26, 27, 33, 34, 35, 36]. 
Table 3: Results of one-way analysis of variance of the effects of the different production 
factors on particle size distribution 
Factor 
PCL-based formulations PDLLA-based formulations 
Coefficient p-value Coefficient p-value 
Drug loading (%w/w) - X1 -0.1094 0.017 -0.0906 0.086 
Organic phase conc. (%w/v) - X2   0.0017 0.955 0.0106 0.804 
Organic/aqueous phase - X3 0.1122 0.015 0.1572 0.017 
PVA concentration (%w/v) - X4  0.1289 0.009 0.1878 0.009 
Frequency (kHz) - X5 -0.1228 0.011 -0.1522 0.019 
Liquid flow rate (ml/sec) - X6 0.1517 0.005 0.1917 0.009 
Stirring rate (rpm) - X7 -0.0967 0.025 -0.0878 0.093 
The mean of the triplicates has been used to compute the coefficient and p-values for each factor.  
 
Coefficient values indicated that some of the factors had a positive relationship with the 
span, meaning that the increase in these parameters led to the increase in the span. These 
included: organic phase concentration (X2), organic: aqueous phase ratio (X3), PVA 
concentration (X4), and liquid flow rate (X6). In contrast, the other parameters had an 
inverse relationship with the span, meaning an increase in these parameters caused a 
reduction in the span, which was favorable. These included drug loading (X1), frequency 
of the vibrating orifice (X5), and stirring rate (X7). Such findings were also in agreement 
with other previous reports [25, 33]. 
There was a general agreement between PCL- and PDLLA-based formulations in terms of 
the order of the production parameters affecting their particle size distribution. As shown 
in Figure 3, for PCL-based formulations, the order of the parameters from those with 
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highest impact to those with lowest impact was: Liquid flow rate (X6) > PVA concentration 
(X4) > Frequency of the vibrating orifice (X5) > Organic: aqueous phase ratio (X3) > Drug 
loading (X1) > Stirring rate (X7) > Organic phase concentration (X2). On the other hand, 
with PDLLA-based formulations, the order of the parameters was:  Liquid flow rate (X6) 
> PVA concentration (X4) > Organic: aqueous phase ratio (X3) > Frequency of the 
vibrating orifice (X5) > Drug loading (X1) > Stirring rate (X7) > Organic phase 
concentration (X2).  This indicated that there was a minor difference between the two 
polymers in terms of the parameters affecting their particle size distribution. However, it 
would be more appropriate to consider each polymeric carrier independently during the 
production process in order to achieve optimal results.     
 
Figure 3. Pareto chart for the different production factors affecting particle size distribution 
as expressed in span.  (A): PCL-based formulations, (B): PDLLA-based formulations. The 
higher the length of the bars, the more effect the factor has on span. Bars crossing p-value= 
0.05 indicate statistical significance.  
 
Generally, the increase in drug loading caused a decrease in the span due to the subsequent 
increase in the viscosity of the dispersing particles. This was attributed to the fact that the 
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content of LTZ increased in relation to the polymer (PCL or PDLLA) with higher drug 
loadings, causing a net increase in the overall viscosity of the formulation. As such, during 
partitioning to the external aqueous phase, more viscous organic droplets tend to resist the 
applied stirring forces as compared to the opposed dilute organic droplets, making them 
maintain their shape, size, and homogeneity [37, 38, 39]. In contrast, the increase in 
organic: aqueous phase ratio led to an increased span. This was because the larger volume 
of aqueous external phase relative to the organic phase induced higher potential of 
agglomeration between the partitioning particles, resulting in unalike droplets, and 
consequently polydisperse particles [33].   
The use of PVA was crucial in producing well dispersed droplets during the emulsification 
process. However, the concentration of PVA (X4) should be determined carefully since 
concentrations lower than those required produced agglomerated particles, whereas higher 
concentrations, increased the external resistive forces against the droplets being emulsified 
[40]. The lowest span achieved in this study, was obtained with PVA concentrations of 
0.04% w/v, and the highest span was obtained with PVA concentrations of 0.1% w/v.   
The frequency of the vibrating orifice (X5) significantly impacted the particle size 
distribution. Higher frequency tends to be more effective in generating monodisperse 
microparticles. This was mainly due to the intensive forces applied on the emerging 
droplets from the VOAG, which produced smaller particles that were easier to disperse 
homogenously than larger counterparts [41]. Similarly, liquid flow rate (X6), determining 
how much the VOAG received from the organic phase to generate the microparticles had 
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a significant effect on the span. This was anticipated since larger volumes supplied per unit 
time would produce larger particles that were less likely to uniformly disperse within the 
aqueous phase, leaving the span at its highest values (165).        
Finally, higher stirring rates were more efficient in maintaining an adequately stable 
dispersion of the droplets, leading to narrower particle size distribution [42]. Table 4 lists 
the optimal production parameters identified based on statistical analyses of the Plackett-
Burman design. In some experiments, however, different drug loading percentages were 
used in order to examine their effects on certain outcomes as would be discussed in the 
upcoming sections.             
 
Table 4: Optimal values of the different production factors for yielding the optimal particle 
size distribution as suggested by the model generated from Plackett-Burman design. 
 
Factor 
Drug 
loading 
(%w/w) 
X1 
Organic 
phase conc. 
(%w/v) 
X2 
Organic/ 
aqueous 
phase  
X3 
PVA 
conc. 
(%w/v) 
X4 
Frequency 
  
(kHz) 
X5 
Liquid 
flow rate 
(ml/sec) 
X6 
Stirring 
rate 
(rpm) 
X7 
Optimum 
value 30  1 1:4 0.04  1000 0.17  500  
 
3.2 Morphological evaluation of VOAG-generated particles 
One important limitation in the development of biodegradable polymer microparticles for 
controlled-release drug delivery applications has been the difficulty of specifically 
designing systems exhibiting precisely controlled release rates. Because microparticle size 
is a primary determinant of drug release, we developed a methodology for controlling 
release kinetics employing MDP. As shown in Figure 4, the SEM showed that powder 
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particles using either PCL or PDLLA carriers were spherical in shape with apparently fine 
smooth surfaces and in the micrometer size range, regardless of LTZ concentration in the 
formulation. All particles appeared uniform in size and dimensions, indicating that the 
VOAG technology can generate monodisperse microparticles when PCL or PDLLA were 
used as polymeric carriers and irrespective of LTZ amount loaded. However, particles with 
5% LTZ loading were smaller than those with higher drug loading (30%), which can be 
ascribed to the increased viscosity of the feed solution when the higher LTZ concentration 
was used, possibly resulting in larger droplets accommodating larger amount of dissolved 
drug and polymer [43]. Nevertheless, regardless of formulation composition, particles did 
not form agglomerates, indicating that the amount of PVA used was appropriate for 
providing homogeneous dispersion of the polymeric particles. Other investigators have 
successfully developed monodisperse chitosan-enriched particles for gene therapy using 
an approach referred to as the double walled microsphere technology [42, 44]. 
3.3 Particle size analysis  
Subsequent to size observation with SEM, laser diffraction studies were performed to 
provide a more robust analysis of size and size distribution of the polymeric microparticles. 
As listed in Table 5, the median particle size, also referred to as the volume median 
diameter (VMD), was found to be dependent on LTZ concentration (p<0.5). Thus, the 
measured size increased from 10.9 ± 0.21 µm to 24.7 ± 0.82 µm when LTZ loading was 
increased from 0% to 30% (w/w) in PCL-based formulations. 
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Figure 4. SEM images of PCL and PDLA based formulations of LTZ. (A): PCL 5% LTZ; 
(B): PCL 30% LTZ; (C): PDLLA 5% LTZ; (D): PDLLA 30% LTZ. Each image is typical 
for the observation taken from three different batches. 
 
Likewise, there was an increase in the measured size from 12.9 ± 0.49 µm to 27.3 ± 0.87 
µm when LTZ loading was increased from 0% to 30% w/w in PDLLA-based formulations. 
Size findings, measured by laser diffraction, agree with SEM observations. The significant 
increase in particle size (p< 0.05) might be attributed to the increase in viscosity of the 
VOAG feed solution due to the higher LTZ concentration, resulting in higher resistance of 
the solution to fragmentation into small aerosol droplets [45]. There was no significant 
A B
C D 
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difference between particle size of PCL and PDLLA formulations that were loaded with 
5% (w/w) LTZ, whereas those particles prepared using the PDLLA polymer with 30% 
(w/w) LTZ were significantly larger than PCL formulation counterpart.  
Size distribution in our VOAG technology studies were comparable to those measured for 
standard polystyrene monodisperse microparticles. Upon analysis, the VMD of the 
polystyrene particles were found to have a size of 23.4 ± 2.50 µm and their span was 0.167 
± 0.02, suggesting better monodispersity (i.e. narrower size distribution) of our polymeric 
particles manufactured using the VOAG technology. The advantage of monodisperse 
particles over polydisperse counterparts has been established in terms of insuring a 
predictable controlled drug release [46]. Thus, our investigations established the 
applicability of the VOAG technology for generating highly MDP when PCL or PDLLA 
are used as carriers and LTZ is used as a model drug. 
Table 5. Particle size (VMD) and particle size distribution (Span) for optimized polymeric 
formulations. Span = (90% undersize – 10% undersize) / VMD. 
 
 
Formulation  VMD (µm) Span 
PCL 10.9 ± 0.21* 0.171 ± 0.002 
PCL 5% (w/w) LTZ 14.7 ± 0.67* 0.185 ± 0.01 
PCL 30% (w/w) LTZ 24.7 ± 0.82* 0.162 ± 0.01 
PDLLA 12.9 ± 0.49* 0.179 ± 0.002 
PDLLA 5% (w/w) LTZ 16.3 ± 1.1* 0.195 ± 0.01 
PDLLA 30% (w/w) LTZ 27.3 ± 0.87* 0.178 ± 0.01 
Polystyrene Control 23.4 ± 2.50 0.167 ± 0.02 
Data presented as mean ± SD, n=3. 
(*): Indicates statistical significance at p= 0.05 between same polymer-based groups. 
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3.4 Drug loading and entrapment efficiency studies   
Drug loading approached almost 100% (98.1 to 99.3%) in all formulations, indicating 
negligible drug losses during production, which highlights the economic feasibility of the 
VOAG technology and the successful adaptation of the apparatus. Importantly, the 
entrapment efficiency, representing the actual amount of drug incorporated within the 
polymeric carriers, was also high and significantly increased by increasing LTZ loading 
from 5% (w/w) to 30% (w/w). For each drug concentration, the entrapment of LTZ was 
higher (p <0.05) in PCL formulations compared to those of PDLLA; nevertheless, the 
entrapment values were considerably high regardless of drug concentration and polymer 
type. Thus, the drug entrapment was 89.9% ± 0.08 and 94.1% ± 0.32 for PDLLA-based 
formulations containing LTZ concentrations of 5% w/w and 30% w/w, respectively. 
Similarly, the entrapment increased from 92.4% ± 0.25 to 96.8% ± 0.06 for PCL-based 
formulations when LTZ concentrations was increased from 5% w/w to 30% w/w. The 
direct relationship between drug concentration and entrapment efficiency could be 
attributed to the increase in particle size with increased drug concentration (Figure 4; Table 
5). It is hypothesized here that larger size offers smaller surface area exposed to the outer 
aqueous phase, hence greater drug proportions can successfully be accommodated by the 
particles and initial drug leakage (i.e. burst effect) is retarded. Thus, diffusion of the drug 
from the polymeric system to the aqueous medium would be much lower in large particles 
compared to smaller particle, for each polymer. A previous study with LTZ incorporated 
into polymeric formulations prepared using emulsion-solvent evaporation have shown that 
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larger particles may have lower affinity to the aqueous medium, preserving more drug 
within the polymeric matrix than smaller particles [47]. 
3.3 Physical structure investigations using DSC and XRD 
As shown in Figure 5, DSC thermograms of pure LTZ revealed its crystalline nature with 
a melting point of 186°C, while PDLLA was confirmed to be amorphous with no melting 
point peak. On the other hand, PCL was confirmed to be crystalline with a melting point 
of 63.5°C. The incorporation of LTZ into PCL or PDLLA resulted in conversion of the 
drug into its amorphous form since the melting peak disappeared from all formulations’ 
thermograms. XRD studies were conducted to back up the DSC investigations. As shown 
in Figure 6, XRD diffractograms showed few distinctive peaks of LTZ crystals in 
formulations containing 20% w/w, 25% w/w, and 30% w/w LTZ, which can be attributed 
to drug crystals lying on top of particle surfaces. Although drug entrapment efficiency was 
higher in these formulations as compared to the ones having only 5-10% w/w LTZ, the 
proposed drug crystals on the surface of particles might indicate that the drug concentration 
exceeded its solubility in the polymeric matrix, leaving some particles in their crystalline 
form near or on the top of the surface (48, 49). Thus, findings in this study combined with 
previous observations indicate that incorporation of crystalline hydrophobic drugs into 
hydrophobic matrices is likely to convert the drug into its amorphous counterpart in a 
manner that depends on carrier properties and drug physicochemical characteristics and 
drug concentration in the formulation. 
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Figure 5. DSC thermograms of (A): pure LTZ, pure PCL, and LTZ-PCL formulations, and 
(B): pure LTZ, pure PDLLA, and LTZ-PDLLA formulations. The profiles presented are 
typical for three independent measurements using three different batches. 
 
 
Figure 6. X-Ray diffractograms of (A) pure LTZ, pure PCL, and LTZ-PCL formulations, 
and (B) pure LTZ, pure PDLLA, and LTZ-PDLLA formulations. The profiles presented 
are typical for three independent measurements using three different batches. 
 
3.4 In vitro drug release and kinetic modeling investigations  
In vitro drug release study was conducted to investigate the ability of the monodisperse 
VOAG-generated MDP to provide controlled release of LTZ. In vitro release studies aim 
to predict the release of drug in vivo and its biodistribution profile [48]. The selected four 
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formulations (PCL 5% LTZ, PCL 30% LTZ, PDLLA 5% LTZ, and PDLLA 30% LTZ) 
were investigated for drug release using dialysis membranes in 0.1 M phosphate buffer 
solution (pH 7.4) containing 20% v/v Transcutol®. Transcutol is an established co-
surfactant/cosolvent used in drug release studies and permeation enhancement 
investigations [49, 50, 51]; thus, Transcutol® was used in the present study to facilitate the 
release of the hydrophobic drug LTZ from the polymeric matrix of the monodisperse PCL 
and PDLLA microparticles.  
For the release study to be more robust and thorough, sampling was performed over a 
prolonged period of one month. The prolonged release study is believed to provide an 
advantage since previous investigations on polymeric formulations were limited to shorter 
periods of time. Thus, our LTZ formulations have been studied for potential long-term drug 
release (e.g. monthly administration) to constitute a base for further in vivo studies as 
possible intramuscular depot formulations, which are planned to be one of the dimensions 
of our future investigations.  
Figure 7 represents the cumulative percentage of drug released over time for the four tested 
formulations. The release of LTZ was sustained in which up to 52.7%, 93%, 35.2%, and 
85.4% of the drug was released after 30 days from PCL 5% LTZ, PCL 30% LTZ, PDLLA 
5% LTZ, and PDLLA 30% LTZ, respectively. The overall release of LTZ increased in 
correspondence with the increase in its loading and entrapment efficiency where particles 
with 30% LTZ content showed the highest release rates, whereas those with 5% LTZ 
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content exhibited lower release rates as evident by the release rate constant (k) values 
reported in Table 6.  
 
Figure 7. In vitro release profiles of 5% or 30% w/w LTZ loading in PCL and PDLLA 
microparticles. n=3, bars represent SD. 
 
Table 6. Drug release kinetic modeling of formulations prepared using PCL or PDLLA polymers 
with 5% or 30% LTZ loading. 
Formulation Zero order 
(Phase 1) 
Zero order 
(Phase 2) 
First order Higuchi Hixon-Crowell Korsemeyer-Peppas 
K R2 K R2 K R2 K R2 K R2 K R2 n 
PCL 5% LTZ  5927.4 0.9951 1025.7 0.9939 0.040 0.9696 2.953 0.9833 0.002 0.3457 0.576 0.8203 0.11 
PCL 30% LTZ  5104.6 0.996 1803.7 0.9955 0.115 0.8531 5.224 0.9694 -0.005 0.4623 0.563 0.8521 0.13 
PDLLA 5% LTZ   4551.8 0.9867 708.1 0.9960 0.023 0.9695 1.876 0.9802 -0.002 0.5967 1.230 0.9246 0.08 
PDLLA 30% LTZ   4533.7 0.9958 1751.1 0.9938 0.089 0.8878 4.736 0.9679 -0.005 0.5533 0.549 0.8599 0.13 
The mean of the 6 replicates has been used to compute the K and R2 values for each model 
The increase in drug entrapment efficiency within the polymeric matrix has been reported 
to have an influence on drug release rate [52]. The higher the drug entrapment in polymeric 
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particles, the greater is the propensity of the drug molecules to be present near the surfaces 
or close to the solid/liquid interface rather than the core of the polymeric particle. This 
hypothesis may constitute a justification for the increased rate of drug release from 
formulations that had higher drug loading [53]. The concentration of the drug might have 
exceeded its solubility in the polymer, resulting in coexistence of dissolved and 
undissolved forms of the drug, with the undissolved crystals protruding towards the 
surfaces of the particle, leading to faster drug release for the formulations loaded with 
higher LTZ concentrations. By contrast, in particles with lower drug loading, higher drug 
proportions are expected to be soluble or molecularly dispersed within the polymeric 
matrix, leading to predomination of the amorphous state of the drug, resulting in lower 
drug diffusion rates; this explanation is supported by the earlier XRD data presented in 
Figure 6. For each drug concentration, the release rate was higher in PCL-based 
microparticles compared to PDLLA-based preparations. This might be attributed to the 
smaller particles prepared upon using the PCL polymer, resulting in higher surface area of 
its particles and faster drug release from its matrix.  
The extended release of LTZ for as long as one month suggested the potential of these 
formulations for intramuscular (IM) depot administration; however, this can be confirmed 
only if further in vivo experiments in the future supports this assumption. Data obtained 
from the in vitro release study were fitted to five empirical kinetic models: Zero-order, 
First order, Higuchi model, Hixson-Crowell model, and Korsemeyer-Peppas semi-
empirical model. Release rate constants (k) and correlation coefficients (R2) of the data and 
the corresponding kinetic models were computed for the four formulations and presented 
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in Table 6. As shown in Figure 7, the release profiles of the four formulations were best 
fitted with a biphasic zero-order model where highest correlation coefficient values were 
obtained. The first phase lasted from 0-3 days, whilst the second started after 3 days and 
continued till the end of the study period (i.e. one month). Each phase had distinct release 
rate constants and correlation coefficients. It was observed that during the first phase, there 
was a slight burst effect ranging from 6.0% to 7.9%, due to the rapid release of the drug 
molecules located at the solid/liquid interface of the polymeric particle. However, after 3 
days, the burst effect decreased to a maximum of 2.4% since almost all drug molecules at 
the solid/liquid interface were depleted and the remaining drug portion within the particle 
cores started to be released in a more controlled manner. In other words, the path that the 
drug had to travel to reach the solid liquid interface is becoming longer. A depletion zone 
is created and expands as more drug is released 
Burst effects were observed with PCL-based formulations compared to PDLLA-based 
particles, due to the relatively smaller particle size and higher surface area of the PCL-
based microparticles. The burst release observed with our MDP was much lower than that 
seen in previous investigations where the proportions of drug lost due to burst effect in 
those studies were extremely high (e.g. exceeding 80% of the drug originally loaded). The 
higher burst release has been ascribed to the polydispersity of particles prepared in those 
studies and the fact that these were nanoparticles with higher surface area [11, 54]. Thus, 
our microparticles generated using the VOAG technology represent and advancement with 
a considerable advantage since the potential adverse effects that may occur due to the 
overwhelming burst effect would be diminished. The production of formulations with 
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biphasic zero-order release kinetics entailed that as time elapsed, constant amounts of LTZ 
were released [55]. This is of high importance since these formulations were successful in 
modifying the release of LTZ to become linear, highly predictable, and consistent, which 
is one of the prime achievements of the present study. 
3.5 In Vitro Cytotoxicity Studies 
Cytotoxicity studies were conducted to evaluate the ability of our LTZ loaded MDP 
produced using the VOAG technology to inhibit the proliferation of MCF-7 human breast 
cancer cells in comparison to primary mammary epithelial cells (MEC). The studies were 
conducted by measuring the average number of viable cells after 24 and 48 h treatment 
with pure LTZ powder or VOAG-generated LTZ-loaded microparticles at a range of 
concentrations (100 nM, 1 µM, 10 µM, and 100 µM). Both untreated as well as vehicle-
treated MCF-7 cells were used as controls to quantify the percentage of inhibition of cell 
proliferation.  
As shown in Figure 8, results revealed that LTZ induced a concentration-dependent 
inhibition of cell proliferation, resulting in 11.3%, 39.2, 48.8%, and 74.6% decrease in cell 
number compared to untreated control (p< 0.05) at concentrations of 100 nM, 1 µM, 10 
µM, and 100 µM, respectively. Similar findings have been reported previously [56]. 
During the first 24 hours of cells incubation and as expected, all concentrations of free LTZ 
showed higher cytotoxicity than drug-loaded MDP. After 48 h of incubation, the cells of 
free LTZ treated group began to re-proliferate and the attachment of cells became well at 
72 hrs (data not shown), while the cell viability of LTZ-Loaded MDP group continued to 
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decrease during the experimental period (p < 0.05). This may suggest that the LTZ-loaded 
MDP showed sustained cell inhibition abilities against the MCF-7 cell lines. This 
phenomenon appears to correspond reasonably well to the in vitro drug controlled release 
properties. From the in vitro drug release experiment, it is clearly shown that LTZ can 
gradually be released from the microparticles in a sustained fashion for 30 days, while the 
free LTZ reached the concentration plateau in 12 to 24 h. The sustained cytotoxicity of 
drug-loaded microparticles could be additionally attributed to the internalization of LTZ-
loaded MDP into the cells and the successive drug release from microparticles inside the 
cells, enhancing the action of LTZ and preventing the short acute action of the drug. Similar 
findings regarding the uptake of Nor--lapachone- and Doxorubicin- PLGA loaded 
microparticles by treated cancer cells were previously reported [57, 58, 59]. Our results 
also indicated that our formulations were non-toxic to MEC normal breast epithelial cells 
at all concentrations expect for 100 µM, which indicates that these monodisperse polymeric 
formulations manufactured using the VOAG technology are potentially safe to non-
cancerous cells (Figure 9).   
To the best of our knowledge, this study represents the first report employing the VOAG 
as a manufacturing tool of MDP. Bearing in mind that vibrating orifice technology has now 
reached the realm of manufacturing of novel drug delivery systems (presented in this 
report); the present investigation involving the VOAG technology is expected to open a 
gate for other studies involving other drugs and carrier systems.  
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Figure 8. MCF-7 cell viability following 48 h treatment using different concentrations of 
LTZ microparticles prepared from PCL or PDLLA polymers. Bars represent the average 
number of nuclei of viable cells as compared with untreated controls. Cell number was 
assessed by automated quantitation of DAPI positive nuclei using ArrayScan XTI (Target 
activation module). Data presented as mean ± SD, n=3. (): Indicates statistical 
significance at p<0.05 compared to untreated cells (48-hrs post seeding). (*): Indicates 
statistical significance at p <0.05 compared to untreated cells (24 h post seeding) 
 
Figure 9. MEC cell viability following 48 h treatment using different concentrations of 
LTZ microparticles prepared from PCL or PDLLA polymers. Bars represent the average 
number of nuclei of viable cells as compared with untreated controls. Cell number was 
assessed by automated quantitation of DAPI positive nuclei using ArrayScan XTI (Target 
activation module). Data presented as mean ±SD (n=3). 
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4. Conclusion  
This study presented a novel approach of adopting a vibrating orifice technology for 
designing monodisperse polymeric microparticles. LTZ was incorporated within either 
PCL or PDLLA carriers in order to optimize its non-linear release profile in vitro. Plackett-
Burman experimental design was successful in identifying the most significant factors 
affecting particle size distribution to optimize the prepared particle. The resultant 
microparticles were characterized for particle size, size distribution, and morphology, 
which confirmed their narrow size distribution (Span values were smaller than those 
measured for monodispersed latex particles used for quality control and instrument 
calibration). LTZ loading approached 100%, and entrapment efficiency values were very 
high for all formulations, reaching up to 94.1% and 96.8% for PDLLA and PCL 
formulations, respectively. Importantly, in vitro release studies revealed that LTZ release 
from the formulations was constant, time-independent, and followed bi-phasic zero-order 
kinetics. In vitro cytotoxicity showed that PCL and PDLLA formulations prolonged the 
cytotoxic effects of LTZ on MCF-7 cells at various concentrations. Importantly, these 
formulations showed no signs of toxicity on normal breast cells at all concentrations except 
for concentrations as high as 100 µM. The findings of this study are promising as they 
indicated that such MDP might serve as new LTZ formulations for monthly administration 
that offered better release profile, which may potentially result in minimal adverse effects. 
Future studies will include in vivo investigations using breast cancer animal models to 
explore the validity of our therapeutic assumption. 
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